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Poris,Fmnce 
O&&vm. We evakted tbe pfevaleuce aad proguostic signif- 
ieamx ofbaasht fipcarw isesesth despite beta-adrf!* 
ih&adehpatieutswitbcoroaaryarterydisease. 
Several studii (l-4) have demonstrated that the presence of 
transient episodes of myocardial ischemia mostly silent, de- 
tected by ambulatory electrocardiographic (ECG) monitoring 
was related to an increased risk of adverse cardiac outcome. 
However, the relation between survival and the detection of 
transient ischemia on monitoring in patients with stable angina 
is not yet extablislled (5). 
Standard antianginal regimens, directed toward symptom 
control, have been shown (6) to reduce the frequency and 
Fmm rbe Cl&al pbarmrdoey Unit, Saint-Antoine Hqital: l Statistiil 
bit iJ3E. ltwtnt SC4. FxttIt6 tie Wskitte %ii-Atttdne: tHdter Monitorhe 
in group I, p = 0.04). Cumoiative perceotagc ofdeatb or mywar- 
dial infarctian, or both, teaded to be bigber in groap I at 
30 aontbs (17% vs. 5% in gmmp ii, p = 0.09). Cot-ouaq 
angiofhsty aad bypass wgery were si@ficaatiy more fkqueat 
in gnmp 1 (p = 0.01 and 0.0008, respwtiwly). Transient iscbemia 
was associated with a biir cunndatie probability of adverse 
eveets(p=o.oQ4).~naplberocarmaary~es,~of 
tma.sieat iscbemii and beta-blocker withdrawal were tbe only 
siguii*tpmgnosticfactwofcardiaceventsintbeCoxmudel 
IngrosaI~ts,~rel9~eltruardofeprdiaeeventswas 
ioesossedthreelddwbeabeta-blockartberapywasia~pted. 
Cuach*FioasTbffedtlttiSUggeStthtU1)tBe-~Of 
traItsieatiscltemiadespitebeta-bbJeberttterapyidentinesasobset 
ofbigbriskpatieatswitbcorwaryarterydisease,aad2)tbe 
interraption of beta-blocker therapy &reases tbe risk of adverse 
cardiac ewats. 
NAm can f?udioi 1996;27:1586-91) 
duration of transient ischemic episodes on ambulatory ECG 
monitoring. Among these regimens, beta-blocker therapy pre- 
vents the greatest proportion of transient ischemic episodes 
and is therefore the most effective monotherapy (7). Although 
a recent study (8) has suggested a link between improved 
outcome and beta-blocker treatment of transient myocardial 
ischemia, the clinical long-term benefit of reducing transient 
ischemia on ambulatory monitoring is unknown. Furthermore, 
the reported persistence of transient myocardial ischemia 
despite continuous beta-blocker therapy among 40% of pa- 
tients with stable coronaty disease (9,lO) may point to a subset 
of high risk patients with coronary artery disease, but no 
morbidity or mortality study has yet addressed this question. 
Moreover, the impact of withdrawal of beta-blocker therapy in 
these patients remains unknown. The purpeses of thii study 
were to evaluate the prevalence of transient ischemia detected 
by ambulatory ECG monitoring despite beta-blocker therapy, 
its long-term prognosis and the impact of withdrawal of 
‘beta-blocker therapy in ‘patients whh stable angina due to 
coronary artery disease. 
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Methods 
Patid I&&MI. The study patients were drawn from the 
subjects of a 2-week double-blind randomized placebo- 
controlled trial carried out at 39 cardiology centers between 
January 1990 and April 1993. That trial evaluated the short- 
term ew of combined therapy with a beta-blocker and a 
calcium channel blocker (amlodipine) in reducing transient 
ischemia (11). 
Patients were eligible for the present study if they met the 
following criteria: 1) coronary artery disease documented 
either by coronary angiograms shoutig ~50% diameter ste- 
nosis in at least one major coronary artery or by previously 
documented myocardial infarction; 2) pretreatment with a 
beta-blocker for 22 weeks; 3) stable angina, defined as stable 
exercise angina without angina at rest; 4) exercise-induced 
ischemia within 6 months before study entry, defined as the 
presence of ?l-mm horixontal or downsloping ST segment 
depression persisting 80 ms after the J point during an exercise 
ECG (standard BNW protocol or treadmill); and 5) age 18 to 
75 years. 
Patients who had any of the following criteria were ex- 
cluded: 1) myocardial infarction within 1 month of study entry 
or cardiac surgery in the mecedmg 2 months; 2) unstabJe 
an& 3) atrial arrhythmias, bundle branch biock, sinus 
brahlcardia, atrioventricuhu node block, sick sinus syndrome, 
Wolff-Park&on-White syndrome or presence of a pacemaker, 
4) ST segment depression 21 mm due to left ventricular 
hypertrophy or conduction defects or any other condition that 
might interfere with interpretation of ST segment depres&n; 
5) codtant therapy with digitalis or antiarrhythmic drugs 
with the exception of amiodarone; 6) uncontrolled hy- 
pertension or hypotension (supine systolic blood pressure 
~90 mm Hg); and 7) renal or hepatic failure. 
The protocol was approved by the Pitit Safp&i&re Univer- 
sity Hospital Ethic Committee. All the patients gave informed 
written consent for participation before enrolhnent in the 
study. Among the 313 eligible patients who underwent 48-h 
ambulatory ECG monitoring, 84 patients with ischemic ambu- 
latory monitoring criteria were randomixed in the Z-week trial. 
Because only patients with ischemic ambulatory monitoring 
criteria entered the short-term study, physicians were noi 
blinded to patient data. All 313 patients entered the tong-term 
follow-up study including the 84 patients who completed the 
short-term combiied beta-blocker-calcium autagonist trial. 
Ambuiatury ECG mositusiug. Continuous 48-h two- 
channel ambulatory ECG recordings were obtained by using 
l-mm/s analog AM tape recorders (EEA medical model 2448) 
witha~~uencyban~betweenO.Q5aodMHz~3dB.AU 
tapes (C 120) were sent to a core ECG analysii laboratory, 
where they were scanned at 120 times real speed on a 
computerized Elatec system (EEA medical, Montrouge, 
France) under continuous visual inspection of an experienced 
physician unaware of treatment assignment. Real-time print- 
outsshowingsTse.gmentabnormalitieswerealsoblindly 
reviewed by two p4ysi&m. To ensure uniform quality of 
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record&s among different investigation centers, reference 
tapes were sent to the core ECG analysis laboratory before 
starting the study and were found compattble. Ambulatory 
Holter recordings were obtained born pre-jelled e- 
positioned after careful skin preparation to record bii 
leads (V, to V, and V,). Baseline FCG recordii were 
performed on each patient before and after hyperventilation 
and postural maneuvers were carried out to ensure the absence 
of artifactual ST segment depression. Patients were instructed 
to press an event button on the record if they had an episode 
of angina and to note the time and duration of any symptom in 
a provided diary. Because of the great variability of transient 
ischemia in ambulatory patients with coronary artery disease 
(12) and to inxease the speciticity of tbe detection (13,14), 
patiena were required to have either four or more ischemic 
episodes or a total duration of ischemia 220 min, or both or 
48-h ambulatory ECG recordings in order to be quaftied in tbe 
group with transient ischemia. An ischemic episode was de- 
fined as zl-mm horizontal or down&rpmg ST depress&m 
persisting 88 1115 from the J point and lasting ri min in 
consecutive beats and separated from other episodes by 
sl min (12). The maximal heart rate during the ischemic 
episodehadtobe<12ObeaMnin.Anepiso&waslabeled 
silent or symptomatic on the basii cf details recorded in the 
patient’s diary. 
Follow-up. The pbysiciars in charge of the 313 patients 
were twice contacted to armplete a questionnaire (once be- 
tween December 1992 and April 1993 and again between 
JanuaryandApril1994).Tbeyhadtodeterminetheoccur- 
rence of &th or a coronary event, or both. A coronaty event 
was defined as myocardial infarction, need for revascularira- 
tion by percutaneous tra&uminaJ comnaty augk@asty or 
coronaryarteryblrpasssurgery,orwotxeningangina.The 
decision to perform a revasadarixation pmcedure or to change 
medicatio~orbo&wasdetenuinedbythephyMmsonthe 
basis of their nvn medical pm&es independentIy of the 
Coordination Cominili,tee of the study. Dei& : as da&&l as 
cardiac or ~oucardiac. Death was c&s&d as pardiac if it was 
duetoadocumeotedcardiaccausesuchasfatatmyocardial 
inf~arrhythmias,cardiacfailureorsuddencardiacarrest 
thatocarrredwithin1hoftheolrsetirf~~o~.Deathdue 
to auy other cause was classi8ed as noncard&. Myocardial 
inf~wa.sde6nedbyehestpainwithassociatedEcG 
changes and crearine kinase patteNs. 
statistical taidysh statistical analysiswis perfoNIed with 
use of SAS (Stat&t&l Anaiysii System) computer @wane. 
Results are expmssed as frequency for categoric vzmbRs, 
me3o -C SD for continuous variables Comparisons between 
groups were performed by using the Student unpaired r test of 
s&p&awe for continuous variables and two-tailed &square 
test for categoric variables. Normorma8y dishibuted data were 
compare4f with 0-e nonpardmetric Wikoxon rank-sum test. 
Kaplan-Meier smvival estimates ofthe cumulative pNbe 
tiesofthewtcomesatagiventimearerecomparedrvithtbe 
kqyarlk test (15). Multivar& cox proportional bazuds 
modelwasusedtoassesstherelatbepr~vahtesof 
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Table 1. Baseline Demographic and Clinical Chamclerictics 
of Patients 
Gnntp I: Group II: 
With Ischemia Without lschemia p 
(n = 81) (n=229) VallIe 
Age*) 6n+ IO 6UZY O.U2 
Male YIP: Y3pc 0.46 
Dumtbn of angina (mo) 50 I 53 54 + 57 0.66 
Asymptomatic patients 43c* 479 0.54 
previous myaardii infarction 63q 64? 0.86 
Previous PKA 3Fi 23% 0.52 
E’rekus CABG 2Jc; 3% 0.7X 
Ciite smoker 607 465 0.03 
Hypxtension 44q’ 3tE 0.02 
Diabetes 13? 117 0.67 
Heart fate at rat (beatvmin) h3 + 10 hhr11 0.13 
h4edicatimts wd 
Antiaggregating agent 71ci MOr 0.06 
ACE inhibitor 147 II% 0.42 
Nitrate 425 26% O.OW 
Diuretic drug 1w II% O.tX5 
Amiiarune 1% 36 0.69 
Drai antimaphting agent 54 147 0.02 
Values are expressed as man value 2 SD or percent of patients in group. 
ACE = angiotemin-converting enzyme: CAEG = mrottay artery bypas 
surgery, MI = myocardiai infarction: PTCA = percutanewr tmnsluminal 
cxxmlmy an~ty. 
TaMr 2. Findings During 4X-h Ambulatory 
Electrocardioaraphic Monitorinn 
Group I: Group II: 
Wii!! lschemia Without lschemia p 
(n = &I) (I3 = 225) val!Jc 
Episodes of ST 1 i48 h (no.) 
Mean duration of ST J ,episode 
(min) 
Heart rate during ischemr. 
(beats~min) 
Silent ischemic episcdes 
7.0 f 5.4 0.3 2 1.2 O.OWl 
25 2 26 92 13 O.wol 
78’15 co+ I5 o.Nnl7 
895; 91% 0.7CQO 
Data are presented as mean value + SD or percent of irhemic epiwbs 
ST 1 = ST segmment depression. 
different variables considered likely to have a clinically impor- 
tant association with outcome during follow-up. These vari- 
ables were age, gender, hypertension, diabetes, history of 
cigarette smoking, history of previous myocardial infarction, 
number of anginal episodes, number of coronary artery steno- 
ses, occurrence of transient &hernia on ambulatory ECG 
monitoring and beta-blocker withdrawal during follow-up. 
Because the exact date of interruption of beta-blocker therapy 
was tmknown, this interruption was entered in the Cox model 
as a tixed covariate and not as a time-dependent covariate. In 
addition, the interactions between factors found significantly 
linked to the occurrence of cardiac outcomes were tested. 
Results 
CIInIcaI cItara&&tics. Table 1 shows the baseline char- 
acteristics of the’313 study patients. With the exception of 
hypertension and cigarette smoking history, all the clinical 
characteristics including age, gender, prevalence and mean 
duration of angina, previous myocardial infarction history, 
previous revascularixation procedures, prevalence of diabetes 
and heart rate at rest were similar in the patients with (group 
I) or without (group II) ambulatory ECG monitoring criteria 
for transient ischemia Coronary angiography was performed 
in 276 patients (88%) with 178 angiographies within 1 year 
before inclusion. The mean number of coronary stenoses was 
2 It 0.9 in both group I and group II, with a similar distribution 
of stenoses in the two groups: one-vessel disease in 31%, 
two-vessel disease in 35% and three-vessel disease in 34% of 
patients. Comparison of the mean left ventricular ejection 
fraction evaluated by ventriculography revealed no significant 
difference between the two groups (62% + 12% in group I vs. 
59% ir 13% in group II). Nitrates and diuretic drugs were 
prescribed more often in group I patients, whereas the pre- 
scription sf uil oral anticoagulant agent was more frequent in 
group Il. 
Ambulatory ECG monitoring resa1t.s. The results of 4fl-h 
ambulatory monitoring among the 313 patients are summa- 
rized in Table 2. Eighty-four patientc (27%) had the required 
ECG recording criteria for myocardial ischemia (group I). In 
these patients, the mean number of episodes of transient 
ischemiaM8 h was 7 + 5, of which 89% were silent. Heart rate 
at onset of &hernia was significantly lower in group I patients 
(78 5 15 vs. 90 2 15 beats/min in patients without &hernia 
[group II] p = 0.0007). 
CIinicaI outcome. The mean duration of follow-up was 
21 2 9 months (range 1 to 37, median 22). Of the 313 patients, 
27 patients (3 of 84 in group I and 24 of 229 in group II) were 
lost to follow-up. This proportion (8.6%) was not significantly 
different between groups. During follow-up, 5 of the 84 
patients in group I died (including 4 who died of cardiac 
causes), 3 had a myocardial infarction, 11 had worsening 
angina and 25 underwent coronary angioplasty or bypass 
surgery; a total of 28 patients in this group had one or more of 
these events during follow-up. of the 229 patients in group II, 
6 died during follow-up (4 from cardiac causes), 9 had a 
myocardial infarction, 24 had worsening angina and 19 re- 
quired coronary angioplasty or bypass surgery; a total of 40 
patients in this groud had one or more events during follow-up. 
The addition of amlodipine to beta-blocker therapy did not 
significantly decrease the number or duration of transient 
ischemic episodes on ambulatory ECG monitoring during the 
‘L-week treatment period (13) and dim not influence the 
long-term outcome of the patients. 
Revascularixation procedures (coronary angioplasty, bypass 
surgery) were required significantly more often in group I (with 
&hernia). At the 3Omonth follow-yr date, the need for bypass 
surgery was 18% in group I versus 6% in group II (p = O.OO@?), 
whereas coronary angioplasty was performed in 13% of pa- 
tients in group I versus 9.0% in group II (p = 0.018). These 
differences were already sign&ant after 1 year (p = 0.002 and 
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Follow-up mc4wn, 
Fwre 1. Kaplan-Meier estimates of the probability of event-free 
survival during follow-up in the 84 patients in group I with transient 
ischemia (I+) and the 229 patients in gruup II without irhemia (I-) 
as detected by ambulatory ECG monitoring. Arrow shows the results of 
the first questionnaire at the IO-month follow-up date. CI = confi- 
dence interval; HR = hazard ratio. 
0.016, respectively). No signilicant differences between groups 
were observed with regard to mortality or clinical morbidity 
outcome (myocardial infarction or worsening angina). Hnw- 
ever, a trend toward increased probability of death was ob 
served in group I. The rate of death, infrequent until 1 year in 
both groups, reached 14.6% in group I patients versus 2.9% in 
group II patients at the 30-month follow-up date (p = 0.093). 
Figure 1 shows the probability of event-free survival when 
aii coronary events are combined. The prognosis was clearly 
worse in group I at all follow-up times, with a relative hazard 
of 2.0 (95% confidence interval ICI] 1.2 to 3.4, p = 0.001). This 
difference was already significant on the first questionnaire, 
corresponding to a follow-up date of 10 months (p = 0.048). 
The cumulative event-free sutvival rate in group I versus group 
II patients was 70 2 5% versus 87 t 2% at 1 year, 67 t 5% 
versus 80 + 3% at 2 years and 58 2 8% versus 76 t 4% at 
30 months. 
Multivariate analysis showed that among all the variates 
entered in the Cox model. three were prognostic factors of a 
worse coronary outcome; these were (in decreasing impor- 
tance) beta-blocker withdrawal during follow-up, presence of 
transient ischemia on ambulatory ECG monitoring and num- 
ber of coronary artery stenoses on angiography (Table 3). 
Beta-blocker treatment was withdrawn among 25% of the 
patients in group II in contrast to 14% in group I (p = 0.04). 
None bf the tested interactions were found statistically signif- 
icant. The trend toward greater mortality observed in patients 
with ischemia was not related to a greater frequency of bypass 
surgery. Hazard ratio of ambulator)/ &hernia was not changed 
with tbe introduction of the bypass surge9 variabIe in the Cox 
model’(hazard ratio 29, 95% CI 0.8 to IO.9 and hazard ratio 
3.0, 95% CI 0.8 to 11.1 before and after, respectively, intro- 
duction of this variable. Moreover, no sign&ant interaction 
was observed; therefore, mortality determined according to the 
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Table 3. Multivariate Cox Proportional Hazards Regression Model 
of Time to Cardiac Events or Death 
Il.% 
I.14 
0.w 
0.70 
1.27 
0.68 
I.(6 
111 
1.91 
3.m 
95% confidem 
hltewal 
0.x5-1.74 
O.Bl-3.34 
lm-IM 
0.26-m 
0.70-2.31 
O39-I.17 
a99-I.1 I 
l.f12-I.% 
l.W-336 
I .65-5.79 
P 
VdUe 
0.8884 
llm 
u.lmr2 
II.4604 
0.4240 
0.1686 
wt+s 
0.0356 
0.8270 
WJI 2 
‘Relatwc hazard of cardiac events or death in patienlr rho had the factor a\ 
Opposed to those who did wt. AEM = ambulatory ECG monimri~ 
presence or absence of ambulatory &hernia was similar with 
or without revascularization. 
Figure 2 shows the probability of coronary event-free 
survival among patients classified by the presence or absence of 
transient ischemia and the interruption or continuation of 
beta-blocker treatment. The group with the best prognosis 
chosen as reference (HR in Fig. 1). comprised patients without 
transient ischemia who continued beta-blocker treatment dur- 
ing follow-up. The group with the worst prognosis (sixfold 
increase in risk of a coronary event) comprised patients with 
transient ischemia in whom beta-blocker therapy was din- 
tinued. 
Discussion 
The progiostic significance of trdusient myocardial isch- 
emia has already been demonstrated, but whether the treat- 
ment of transient ischemia can a&t the long-term morbidity 
and mortality of patients with stable coronary artery disease 
remains questionable. In this study over a medii follow-up 
FF 2. Kaplan-Me& estimates of Ihe probability of event-free 
survival among patients in gronp 1 with ischemia (IL) and patients in 
-mup II without ischemia (I-) who had continued (B+) or inter- 
rupted (3-) beta-bktcker treatment during follow-up. HR = hazard 
ratio; numbers in brackets indiie !?SV ax&&nce interval. 
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@xl of 22 months, cardiac events including death, myocar- 
dii infarction, worsening angina and coronary angioplasty and 
bypass surgery procedures were recorded in 313 patients. The 
results show that persistence of a myocardial ischemia on 
ambulatory ECG recordings, in patients with stable angina 
receiving beta-blockers therapy, is a powerful predictor of 
cardiac events, Considering all the noninvasive and invasive 
dam, the multivariate analysis showed two other factors with 
an independent prognostic value: 1) withdrawal of beta- 
blocker therapy during follow-up, and 2) the number of 
coronary artery stenoses. 
Number of corn- artery steaoses. That the number of 
coronary artery stenoses on angiography could be a predictor 
of cardiac outcome is not surprising (16-20). This result is in 
agreement with studies (17,19) showing that after myocardial 
infarction, the prognosis of patients is related to the patency of 
coronary arteries and is impaired when arteries remain oc- 
cluded. hiore interesting were the results of the angiographic 
data. In this study, the mean number of coronary stenoses was 
not significantly different between the groups with or without 
ischemia. Thus the presence of ambulant myocardial ischemia 
is not dependent on the extent of coronary lesions but can be 
associated with a poorer cardiac prognosis. 
Gecnneoee d transient Ischemla. Numerous studies have 
demonstrated that in patients who have unstable angina or 
have had an acute myocardial infarction, coronary artgioplasty 
or bypass surgery, the presence of transient myocardial isch- 
emia on ambulatory ECG monitoring significantly alters the 
prognosis from that of patients without &hernia (1,21-23). 
The prognostic significance of trsirsient &hernia on ambula- 
tory monitoring in patients with stable coronary artery disease 
has also been evaluated in three important studies (2,3,24), 
which showed that the occurrence of transient &hernia on 
monitoring was a significant predictor of unfavorable coronary 
outcome. The results of our study are consistent with these 
previous reports. However, no long-term follow-up study has 
been performed in a large group of patients initially screened 
for presence or absence of transient myocardial ischemia while 
receiving beta-blocker therapy. 
Recently the ASIST study (9) suggested that the reduction 
of transient ischemia with atenolol in patients with mildly 
symptomatic coronary artery disease was associated with a 
reduced risk of adverse outcome. Among the 154 patients 
treated with atenolol, 42% continued to have transient isch- 
emia on ambulatory monitoring after 52 weeks of treatment. 
The most powerful prediior of event-free survival was the 
absence of iscltemia on monitoring after 4 weeks of beta- 
blocker treatment. 
To test the hypothesis that the suppression of transient 
ischemia would reduce the risk of adverse outcome among 
patients with carmary artery disease, the ACIP study (25) 
evaluated the benefit of a prespecified treatment strategy 
(iemia-guided, angina-guided and revasc&rimtion pmce- 
dures) in improving the event-free survival at 1 year. Revascu- 
larization seemed to have a sign&ant advantage over drug 
therapy in improving prognosis. Surprisingly, no death oc- 
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cuned in the group assigned to a revascularization procedure, 
and the mortality rate in this group was significantly less than 
that in the angina-guided strategy group but similar to that in 
patients assigned to an &hernia-guided strategy. Tbe results of 
combined incidence of myocardial infarction and death were 
similar. Nevertheless, the ischemia-guided therapy did not 
seem to improve the clinical outcomes over that of angina- 
guided therapy. The follow-up period of that study was rela- 
tively short. Patients in the ischemia-guided arm did not 
receive the drugs at a large enough dosage to suppress 
&hernia, and some of the patients were not given any drug at 
all. Each of the three strategies was only partially effective in 
suppressing &hernia as >40% of patients had penistent 
evidence of transient &hernia. No statistical outcome sub- 
group analysis was performed in the ACIP study, grouping 
patients assigned to the ischemia-guided strategy on the basis 
of persistence or absence of transient ischemia on ambulatory 
ECG monitoring. The results of our study addressed this 
question and identified a subset of high risk patients with 
coronaty artery disease. 
Reta-bhxker withdrawal. One major finding of the present 
study is that the relative hazard of having a cardiac event was 
increased threefold in patients with transient ischemia whose 
heta-blocker therapy was interrupted during follow-up as over 
that in patients with ischemia and continuous beta-blocker 
therapy. This difference was even greater (siiold) when the 
outcome of patients with transient ischemia and interrupted 
beta-blocker treatment was compared with that of patients 
without &hernia and continuous beta-blocker therapy. Several 
studies have demonstrated the existence of a possible rebound 
phenomenon with an increased incidence of angina, myocar- 
dial infarction, arrhythmias and death in patients with angina 
after abrupt interruption of beta-blocker therapy (26,27). 
Several mechanisms for this phenomenon have been sug- 
gested, including the presence of unmasked up-regulated 
myocardial he&-receptors after abrupt beta-blocker with- 
drawal (28). Recommendations for gradual interruption of 
beta-blocker treatment have been established. However, the 
problem of the duration of a long-term beta-blocker therapy in 
patients with coronary artery disease remains unsolved. Be- 
cause the highest rate of death after hospital discharge of 
patients after myocardial infarction occurred during the 1st 
year in controlled randomized cliical trials (29) many inves- 
tigators suggested that beta-blocker treatment needed not to 
be continued after 1 or 2 years. Previous myocardial infarction 
occurred, on average, 5 years before the study entry of our 
patients. Therefore, although our patients were not at the 
highest risk period, interruption of beta-blocker therapy during 
follow-up increased threefold the risk of a coronary event. No 
long-term study has yet evahiated the effect on prognosis of the 
interruption of a beta-blocker therapy in patients with stable 
coronary artery disease after 1 or 2 years of treatment. Such a 
large prospective clinii trial would require &!O,OOO patients 
followed up for some years and remains to be undertaken (30). 
L.hitatloaa ef the stmiy. The sign&ant increase in the 
event rate of coronary angioplasty and mss surgery in 
patients with transient ischemia in our study might have been 
in part influenced by the possible tendency of physicians to 
recommend invasive therapy in light of the results of the 
ambulatory ECG monitoring. However, a trend. although not 
significant, toward increased risk of death was evident in the 
group with transient ischemia and was not related to the 
greater frequency of revascularization procedures. Gill et al. 
(22) recently showed the significance of myocardial ischemia 
detected by ambulatory monitoring in 400 patients early after 
acute myocardial infarction. The difference between the mor- 
tality rates at 1 year-11.6% among patients with ischemia and 
3.9% among those without ischemia-was highly significant 
(p = 0.009). These percentages were similar in our study over 
a median follow-up interval of 22 months (15% vs. 3%). Our 
study is also limited by a lack of precise information on the 
time of and reason for beta-blocker withdrawal. However, we 
assume that this bias does not significantly modify ths inter- 
pretation of the results because, although beta-blocker with- 
drawal was significantly more frequent in the low-risk group II 
patients (without ischemia), it remained the most significant 
predictor of unfavorable outcome. This observation reiuforces 
the possible impact of beta-blocker interruption. 
Gmdssions. Our results suggest that 1) the occurrence of 
transient myocardial &hernia despite beta-blockade is associ- 
ated with an unfavorable outcome in patients with stable 
comwy artery disease, and 2) interruption of beta-blocker 
therapy during follow-up is the most powerful pred&tor of 
coronary events. No large scale long-term study has yet demon- 
strated the impact of suppression of ambuhmt ischemia on benefit 
and improved prognosis. Although this hypothesis iz conceptually 
attractive, it remains to be proved. Further clinical srudii such as 
ACfP II study will p&ably determine the role of tlx suppression 
of transient ischemia on ambulatory ECG monitoring in pxvent- 
ing death in patients with coronary artery d&ease. The question of 
the impact of interruption of beta-blocker therapy should be 
spec&ally addressed in these clinical trials. 
We are indebted 10 Dominiqw OKtagliola, PhD for statistical conwhatioa. We 
are also grateful IO Sandrine Maquenhem for excelknr secretarial work and lo 
Armick Guiilardeau for assistance throwhoot the rludv. 
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